|
KMID : 1170320100160030163
|
|
Korean Journal of Health Economics and Policy
2010 Volume.16 No. 3 p.163 ~ p.187
|
|
|
Challenges in drug re-evaluation system based on health technology assessment
|
|
Bae Eun-Young
|
|
|
Abstract
|
|
|
|
Korea is among the countries which have experienced rapidly increasing drug expenditures. According to OECD health data, the annual growth rate of Korean drug expenditure was around 10% from 2001 to 2006. To control and keep this increase rate within sustainable levels, and attain the efficiency within the system, the Korean government announced the introduction of a positive list system in May 2006. Under the positive list system, only drugs which have established their value in terms of clinical efficacy and cost-effectiveness can be listed. In addition to new drugs, listed drugs have also been scheduled to have their value re-evaluated during the period from 2007 to 2012. Based on the evaluation results, existing drugs with low added value will be de-listed. The Health Insurance Review and Assessment Service(HIRA) has a mandate to review all listed drugs, and it reviewed migraine and hyperlipidemia drugs as a pilot project in 2007. Since HIRA opened its assessment reports and the preliminary decisions of the committee, there has been a debate over the assessment methodology and decisions made by the committee. This study will discuss the issues which have been raised in Korea during the re-evaluation of two therapeutics groups. These issues are: the relation between scientific assessment and decision making, the use of cost-effectiveness data in the determination of ceiling price, and the way social values are reflected in reimbursement decisions.
|
|
|
KEYWORD
|
|
|
Drug re-evaluation system, health technology assessment, cost-effectiveness, social value
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|